Retinal Vein Occlusion
Conditions
Keywords
ischemic index, Ultra-wide field fundus fluorescein angiography, vascular leakage index
Brief summary
The changes of ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion by ultra-wide field fluorescence angiography (UWFA)
Detailed description
In this study, the ischemic index and vascular leakage index, and the effect on macular edema and neovascularization in retinal vein occlusion will be evaluated by ultra-wide field fluorescence angiography (UWFA). UWFA has a wider range than conventional angiography, and can clearly observe the peripheral retina. The purpose of this study is to quantitatively analyze these changes and investigate the effect on macular edema and neovascularization secondary to retinal vein occlusion.
Interventions
None listed
Sponsors
Renmin Hospital of Wuhan University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female aged 18 years or more 2. Patients with a diagnosis of CRVO,BRVO or HRVO without macular edema 3. Duration of RVO not more than 4 months 4. Naïve patients. Patient with previous RVO (more than 12 months before the inclusion date) which completely resolved (normalization of visual acuity and fundus examination) and who experienced a recurrence of RVO are also considered naive 5. Patient who agrees to participate to the study and who has given his/her written, informed consent
Exclusion criteria
1. Patient with another retinal disease in the study eye: diabetic retinopathy, maculopathy of any cause (age-related macular degeneration, epimacular membrane, myopia, etc) responsible for decreased vision, advanced glaucoma, cataract severely affecting vision and/or requiring surgical treatment during the 24 months study period 2. Active or suspected ocular or periocular infection 3. Active severe intraocular inflammation 4. RVO complicated with neovascularization 5. Patient who has previously undergone laser panretinal photocoagulation, grid-laser or photodynamic therapy, any anti-VEGF or corticoids intravitreal injections in the study eye 6. Patient already included in the study for the treatment of the fellow eye 7. Pregnant or breastfeeding woman 8. Lack of effective contraception for women of childbearing age 9. Patient taking part in an interventional study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in non-perfused areas in different retinal area | Baseline and1，2，3，6，9and 12 months | Change in non-perfused areas in different retinal area from Baseline to 1，2，3，6，9and 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in best corrected visual acuity | Baseline and1，2， 3, 6, 9 and 12 months | Change in best corrected visual acuity from Baseline to 1，2，3，6，9and 12 months |
| Change in central macular thickness | Baseline and1，2， 3, 6, 9 and 12 months | Change in central macular thickness from Baseline to 1，2，3，6，9and 12 months |
Countries
China
Contacts
Primary ContactCZ Chen, PHD
Backup ContactXL Wang
Outcome results
None listed